DSIP at a glance
A fast read for beginners, with evidence strength, route context, safety depth, and community activity surfaced before the deeper sections.
Delta Sleep-Inducing Peptide (DSIP) is a neuromodulatory nonapeptide with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. Originally isolated from rabbit cerebral venous blood by Monnier et al. in 1977 during studies of thalamic sleep induction, DSIP has since been identified in the hypothalamus, limbic system, pituitary, and peripherally in the gut, adrenal glands, and plasma.
DSIP exerts a complex array of neuromodulatory effects that go beyond simple sleep induction. It reduces levels of corticotropin (ACTH) and cortisol, modulates GH and LH pulsatility, exhibits antioxidant activity, and has been shown to normalize circadian rhythms disrupted by jet lag, shift work, or stress. Its stress-dampening profile - lowering ACTH and catecholamine levels while promoting restorative sleep - gives it an adaptogen-like pharmacological signature.
Clinical data, while largely from older Soviet and European studies, showed DSIP to be effective in treating chronic insomnia, withdrawal syndromes (alcohol, opioid, benzodiazepine), chronic pain conditions, and stress-related neuroendocrine dysregulation. A key German study demonstrated significant improvement in polysomnographic sleep quality in insomnia patients. The peptide appears to act less as a direct hypnotic and more as a normalizer of dysregulated sleep-wake architecture.
DSIP is of interest in the peptide research community primarily for sleep optimization, stress axis regulation, and as a potential aid to substance withdrawal. Its low molecular weight and neuropeptide nature raise questions about CNS penetration via systemic administration, though peripheral DSIP receptors and effects on peripheral neuroendocrine organs likely account for at least some of its observed actions.
Key Benefits
Saves this peptide to your Watchlist and helps you find new research, news, and questions later.